Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme
OBJECTIVES: I. Assess the therapeutic activity and toxicities of nitrocamptothecin in
patients with glioblastoma multiforme. II. Determine the overall response, duration of
response, and progression free survival of these patients after this treatment.
OUTLINE: This is a multicenter study. Patients receive nitrocamptothecin orally daily on
days 1-5. Treatment continues every 7 days in the absence of disease progression or
unacceptable toxicity. Patients are followed every 6 weeks until disease progression in the
absence of further treatment.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Eric Raymond, MD, PhD
Study Chair
Gustave Roussy, Cancer Campus, Grand Paris
United States: Federal Government
EORTC-16996G
NCT00005826
March 2000
Name | Location |
---|